|
تقييم الدكتور ريدي محدودة (RDY) DCF |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Dr. Reddy's Laboratories Limited (RDY) Bundle
تبسيط تحليلك وتحسين الدقة مع حاسبة (RDY) DCF! باستخدام بيانات حقيقية من افتراضات Dr. Reddy's Laboratories Limited و Elementable ، تمكنك هذه الأداة من التنبؤ والتقييم والقيمة (RDY) مثل المستثمر المتمرس.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,029.1 | 2,204.8 | 2,491.5 | 2,857.4 | 3,244.2 | 3,648.8 | 4,103.9 | 4,615.7 | 5,191.4 | 5,838.9 |
| Revenue Growth, % | 0 | 8.66 | 13 | 14.69 | 13.54 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| EBITDA | 485.6 | 531.2 | 554.8 | 865.0 | 1,027.6 | 965.0 | 1,085.4 | 1,220.7 | 1,373.0 | 1,544.2 |
| EBITDA, % | 23.93 | 24.09 | 22.27 | 30.27 | 31.67 | 26.45 | 26.45 | 26.45 | 26.45 | 26.45 |
| Depreciation | 144.9 | 148.7 | 137.4 | 146.8 | 172.5 | 217.9 | 245.1 | 275.6 | 310.0 | 348.7 |
| Depreciation, % | 7.14 | 6.74 | 5.52 | 5.14 | 5.32 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 |
| EBIT | 340.7 | 382.5 | 417.4 | 718.1 | 855.1 | 747.1 | 840.3 | 945.1 | 1,063.0 | 1,195.6 |
| EBIT, % | 16.79 | 17.35 | 16.75 | 25.13 | 26.36 | 20.48 | 20.48 | 20.48 | 20.48 | 20.48 |
| Total Cash | 299.1 | 401.8 | 515.6 | 775.7 | 946.8 | 802.7 | 902.8 | 1,015.4 | 1,142.0 | 1,284.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 584.3 | 576.9 | 775.9 | 842.4 | 933.2 | 1,053.4 | 1,184.8 | 1,332.5 | 1,498.7 | 1,685.6 |
| Account Receivables, % | 28.8 | 26.17 | 31.14 | 29.48 | 28.76 | 28.87 | 28.87 | 28.87 | 28.87 | 28.87 |
| Inventories | 407.5 | 527.7 | 591.3 | 565.6 | 738.5 | 805.0 | 905.4 | 1,018.4 | 1,145.4 | 1,288.2 |
| Inventories, % | 20.08 | 23.94 | 23.73 | 19.79 | 22.77 | 22.06 | 22.06 | 22.06 | 22.06 | 22.06 |
| Accounts Payable | 124.9 | 147.5 | 185.6 | 207.5 | 250.4 | 257.4 | 289.5 | 325.7 | 366.3 | 411.9 |
| Accounts Payable, % | 6.15 | 6.69 | 7.45 | 7.26 | 7.72 | 7.06 | 7.06 | 7.06 | 7.06 | 7.06 |
| Capital Expenditure | -71.1 | -146.0 | -221.4 | -219.2 | -318.8 | -266.4 | -299.6 | -337.0 | -379.1 | -426.3 |
| Capital Expenditure, % | -3.5 | -6.62 | -8.89 | -7.67 | -9.83 | -7.3 | -7.3 | -7.3 | -7.3 | -7.3 |
| Tax Rate, % | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 |
| EBITAT | 368.3 | 232.8 | 304.6 | 535.1 | 662.5 | 576.5 | 648.4 | 729.3 | 820.2 | 922.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -424.7 | 145.3 | -3.9 | 443.9 | 295.3 | 348.3 | 394.2 | 443.3 | 498.6 | 560.8 |
| WACC, % | 6.46 | 6.4 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,842.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 572 | |||||||||
| Terminal Value | 12,930 | |||||||||
| Present Terminal Value | 9,471 | |||||||||
| Enterprise Value | 11,314 | |||||||||
| Net Debt | 150 | |||||||||
| Equity Value | 11,164 | |||||||||
| Diluted Shares Outstanding, MM | 834 | |||||||||
| Equity Value Per Share | 13.39 |
What You Will Receive
- Comprehensive Financial Model: Leverage Dr. Reddy's actual data for accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other vital metrics.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling ongoing use for in-depth forecasts.
Key Features
- Comprehensive RDY Data: Pre-filled with Dr. Reddy's Laboratories' historical financials and future projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures.
- Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Multiple Scenario Analysis: Develop various forecast scenarios to evaluate different valuation results.
- Intuitive Interface: Designed to be user-friendly for both experienced professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Dr. Reddy's pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for Dr. Reddy's Laboratories Limited (RDY)?
- User-Friendly Interface: Crafted for both novices and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Dr. Reddy's valuation as you modify inputs.
- Pre-Loaded Data: Comes with Dr. Reddy's actual financial figures for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Dr. Reddy's Laboratories Limited (RDY) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Dr. Reddy's Laboratories Limited (RDY).
- Consultants: Deliver professional valuation insights on Dr. Reddy's Laboratories Limited (RDY) to clients quickly and accurately.
- Business Owners: Understand how large companies like Dr. Reddy's Laboratories Limited (RDY) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Dr. Reddy's Laboratories Limited (RDY).
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Dr. Reddy's Laboratories Limited (RDY).
- Real-World Data: Dr. Reddy's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables that provide clear, actionable results for decision-making.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.